0 XP   0   0   0

AFT Pharmaceuticals Ltd
Buy, Hold or Sell?

Let's analyse AFT Pharmaceuticals Ltd together

PenkeI guess you are interested in AFT Pharmaceuticals Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of AFT Pharmaceuticals Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about AFT Pharmaceuticals Ltd

I send you an email if I find something interesting about AFT Pharmaceuticals Ltd.

Quick analysis of AFT Pharmaceuticals Ltd (30 sec.)










1. Valuation of AFT Pharmaceuticals Ltd (5 min.)




Live pricePrice per share (EOD)

A$3.55

2. Growth of AFT Pharmaceuticals Ltd (5 min.)




Is AFT Pharmaceuticals Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$34.2m$21.7m$10.1m31.8%

How much money is AFT Pharmaceuticals Ltd making?

Current yearPrevious yearGrowGrow %
Making money$2.5m$2.4m$121.7k4.7%
Net Profit Margin0.0%4.5%--

How much money comes from the company's main activities?

3. Financial Health of AFT Pharmaceuticals Ltd (5 min.)




4. Comparing to competitors in the Drug Manufacturers-Specialty & Generic industry (5 min.)




  Industry Rankings (Drug Manufacturers-Specialty & Generic)  


Richest
#449 / 691

Most Revenue
#258 / 691

Most Profit
#156 / 691

Most Efficient
#112 / 691


Fundamentals of AFT Pharmaceuticals Ltd

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

1.1. Profitability of AFT Pharmaceuticals Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit AFT Pharmaceuticals Ltd earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare AFT Pharmaceuticals Ltd to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of AFT Pharmaceuticals Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY4.5%-4.5%
TTM-5Y1.3%-1.3%
5Y1.3%10Y-2.8%+4.1%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.3%-1.3%
TTM-1.3%-1.3%
YOY4.5%1.6%+2.9%
5Y1.3%0.1%+1.2%
10Y-2.8%1.0%-3.8%
1.1.2. Return on Assets

Shows how efficient AFT Pharmaceuticals Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare AFT Pharmaceuticals Ltd to the Drug Manufacturers-Specialty & Generic industry mean.
  • 0.6% Return on Assets means that AFT Pharmaceuticals Ltd generated $0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of AFT Pharmaceuticals Ltd:

  • The MRQ is 0.6%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 3.7%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.6%TTM3.7%-3.1%
TTM3.7%YOY4.0%-0.2%
TTM3.7%5Y1.7%+2.1%
5Y1.7%10Y-0.5%+2.2%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6%-0.2%+0.8%
TTM3.7%-0.3%+4.0%
YOY4.0%0.1%+3.9%
5Y1.7%-0.1%+1.8%
10Y-0.5%0.2%-0.7%
1.1.3. Return on Equity

Shows how efficient AFT Pharmaceuticals Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare AFT Pharmaceuticals Ltd to the Drug Manufacturers-Specialty & Generic industry mean.
  • 1.3% Return on Equity means AFT Pharmaceuticals Ltd generated $0.01 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of AFT Pharmaceuticals Ltd:

  • The MRQ is 1.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 8.8%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.3%TTM8.8%-7.5%
TTM8.8%YOY11.3%-2.5%
TTM8.8%5Y-3.4%+12.2%
5Y-3.4%10Y-8.9%+5.5%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ1.3%0.5%+0.8%
TTM8.8%0.3%+8.5%
YOY11.3%0.5%+10.8%
5Y-3.4%-0.1%-3.3%
10Y-8.9%0.4%-9.3%

1.2. Operating Efficiency of AFT Pharmaceuticals Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient AFT Pharmaceuticals Ltd is operating .

  • Measures how much profit AFT Pharmaceuticals Ltd makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare AFT Pharmaceuticals Ltd to the Drug Manufacturers-Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of AFT Pharmaceuticals Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY2.8%-2.8%
TTM-5Y2.0%-2.0%
5Y2.0%10Y-1.8%+3.8%
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-0.5%-0.5%
TTM-2.9%-2.9%
YOY2.8%4.3%-1.5%
5Y2.0%3.5%-1.5%
10Y-1.8%2.1%-3.9%
1.2.2. Operating Ratio

Measures how efficient AFT Pharmaceuticals Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of AFT Pharmaceuticals Ltd:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY0.269-0.269
TTM-5Y0.609-0.609
5Y0.60910Y0.821-0.212
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.416-1.416
TTM-1.422-1.422
YOY0.2691.419-1.150
5Y0.6091.434-0.825
10Y0.8211.221-0.400

1.3. Liquidity of AFT Pharmaceuticals Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if AFT Pharmaceuticals Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A Current Ratio of 1.28 means the company has $1.28 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of AFT Pharmaceuticals Ltd:

  • The MRQ is 1.280. The company is just able to pay all its short-term debts.
  • The TTM is 1.974. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.280TTM1.974-0.695
TTM1.974YOY2.359-0.385
TTM1.9745Y2.080-0.106
5Y2.08010Y2.386-0.306
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2801.778-0.498
TTM1.9741.844+0.130
YOY2.3592.166+0.193
5Y2.0802.379-0.299
10Y2.3862.119+0.267
1.3.2. Quick Ratio

Measures if AFT Pharmaceuticals Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare AFT Pharmaceuticals Ltd to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Quick Ratio of 0.47 means the company can pay off $0.47 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of AFT Pharmaceuticals Ltd:

  • The MRQ is 0.467. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.816. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.467TTM0.816-0.349
TTM0.816YOY1.044-0.228
TTM0.8165Y0.832-0.016
5Y0.83210Y1.020-0.188
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4670.659-0.192
TTM0.8160.806+0.010
YOY1.0440.944+0.100
5Y0.8321.016-0.184
10Y1.0201.008+0.012

1.4. Solvency of AFT Pharmaceuticals Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of AFT Pharmaceuticals Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare AFT Pharmaceuticals Ltd to Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.53 means that AFT Pharmaceuticals Ltd assets are financed with 53.4% credit (debt) and the remaining percentage (100% - 53.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of AFT Pharmaceuticals Ltd:

  • The MRQ is 0.534. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.553. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.534TTM0.553-0.019
TTM0.553YOY0.649-0.096
TTM0.5535Y0.753-0.199
5Y0.75310Y0.737+0.016
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5340.439+0.095
TTM0.5530.425+0.128
YOY0.6490.403+0.246
5Y0.7530.412+0.341
10Y0.7370.410+0.327
1.4.2. Debt to Equity Ratio

Measures if AFT Pharmaceuticals Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare AFT Pharmaceuticals Ltd to the Drug Manufacturers-Specialty & Generic industry mean.
  • A Debt to Equity ratio of 114.6% means that company has $1.15 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of AFT Pharmaceuticals Ltd:

  • The MRQ is 1.146. The company is able to pay all its debts with equity. +1
  • The TTM is 1.252. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.146TTM1.252-0.107
TTM1.252YOY1.866-0.614
TTM1.2525Y5.088-3.836
5Y5.08810Y4.580+0.508
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ1.1460.700+0.446
TTM1.2520.704+0.548
YOY1.8660.639+1.227
5Y5.0880.700+4.388
10Y4.5800.715+3.865

2. Market Valuation of AFT Pharmaceuticals Ltd

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings AFT Pharmaceuticals Ltd generates.

  • Above 15 is considered overpriced but always compare AFT Pharmaceuticals Ltd to the Drug Manufacturers-Specialty & Generic industry mean.
  • A PE ratio of 477.97 means the investor is paying $477.97 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of AFT Pharmaceuticals Ltd:

  • The EOD is 565.603. Seems overpriced? -1
  • The MRQ is 477.974. Seems overpriced? -1
  • The TTM is 279.798. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD565.603MRQ477.974+87.629
MRQ477.974TTM279.798+198.177
TTM279.798YOY198.730+81.068
TTM279.7985Y253.613+26.185
5Y253.61310Y189.679+63.934
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD565.603-0.035+565.638
MRQ477.974-0.163+478.137
TTM279.7980.006+279.792
YOY198.7306.167+192.563
5Y253.6137.212+246.401
10Y189.67914.211+175.468
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of AFT Pharmaceuticals Ltd.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of AFT Pharmaceuticals Ltd:

  • The MRQ is 477.974. Seems overpriced? -1
  • The TTM is 1,569.812. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ477.974TTM1,569.812-1,091.838
TTM1,569.812YOY190.439+1,379.373
TTM1,569.8125Y754.690+815.123
5Y754.69010Y611.747+142.943
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
MRQ477.9745.846+472.128
TTM1,569.81212.876+1,556.936
YOY190.43913.819+176.620
5Y754.69039.778+714.912
10Y611.74772.812+538.935

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of AFT Pharmaceuticals Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers-Specialty & Generic industry mean).
  • A PB ratio of 6.12 means the investor is paying $6.12 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of AFT Pharmaceuticals Ltd:

  • The EOD is 7.236. Seems overpriced? -1
  • The MRQ is 6.115. Seems overpriced? -1
  • The TTM is 7.693. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD7.236MRQ6.115+1.121
MRQ6.115TTM7.693-1.578
TTM7.693YOY14.600-6.907
TTM7.6935Y27.004-19.311
5Y27.00410Y24.760+2.244
Compared to industry (Drug Manufacturers-Specialty & Generic)
PeriodCompanyIndustry (mean)+/- 
EOD7.2361.477+5.759
MRQ6.1151.598+4.517
TTM7.6931.660+6.033
YOY14.6002.331+12.269
5Y27.0042.477+24.527
10Y24.7603.068+21.692
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of AFT Pharmaceuticals Ltd.

3.1. Funds holding AFT Pharmaceuticals Ltd

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2021-02-28Commonwealth International Ser-Australia/New Zealand Fund0.04-46000--
Total 0.0404600000.0%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of AFT Pharmaceuticals Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.034-100%0.024-100%0.019-100%0.020-100%
Book Value Growth--1.0001.095-9%1.087-8%1.159-14%1.107-10%
Book Value Per Share--0.4910.457+7%0.312+57%0.214+130%0.203+141%
Book Value Per Share Growth--1.0001.095-9%1.087-8%1.159-14%1.107-10%
Current Ratio--1.2801.974-35%2.359-46%2.080-38%2.386-46%
Debt To Asset Ratio--0.5340.553-3%0.649-18%0.753-29%0.737-28%
Debt To Equity Ratio--1.1461.252-9%1.866-39%5.088-77%4.580-75%
Dividend Per Share----0%0.000-100%0.001-100%0.001-100%
Eps--0.0060.037-83%0.023-73%0.013-53%0.001+450%
Eps Growth--1.0001.443-31%2.008-50%1.559-36%1.499-33%
Free Cash Flow Per Share--0.0250.028-10%0.022+17%0.007+277%-0.001+102%
Free Cash Flow Per Share Growth--1.0000.976+2%1.791-44%0.888+13%0.692+44%
Free Cash Flow To Equity Per Share--0.0120.016-24%0.010+25%0.009+32%0.017-30%
Free Cash Flow To Equity Per Share Growth--1.0000.871+15%2.693-63%1.328-25%-0.264+126%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.059-6%
Intrinsic Value_10Y_max--0.767--------
Intrinsic Value_10Y_min--0.184--------
Intrinsic Value_1Y_max--0.108--------
Intrinsic Value_1Y_min--0.073--------
Intrinsic Value_3Y_max--0.301--------
Intrinsic Value_3Y_min--0.174--------
Intrinsic Value_5Y_max--0.465--------
Intrinsic Value_5Y_min--0.223--------
Net Profit Margin----0%0.045-100%0.013-100%-0.0280%
Operating Margin----0%0.028-100%0.020-100%-0.0180%
Operating Ratio----0%0.269-100%0.609-100%0.821-100%
Pb Ratio7.236+15%6.1157.693-21%14.600-58%27.004-77%24.760-75%
Pe Ratio565.603+15%477.974279.798+71%198.730+141%253.613+88%189.679+152%
Peg Ratio--477.9741569.812-70%190.439+151%754.690-37%611.747-22%
Price Per Share3.550+15%3.0003.400-12%4.445-33%3.228-7%3.063-2%
Profit Growth--1.0000.983+2%1.772-44%1.359-26%1.332-25%
Quick Ratio--0.4670.816-43%1.044-55%0.832-44%1.020-54%
Return On Assets--0.0060.037-84%0.040-85%0.017-64%-0.005+188%
Return On Equity--0.0130.088-86%0.113-89%-0.034+365%-0.089+795%
Total Gains Per Share---0.034-100%0.024-100%0.020-100%0.021-100%
Usd Book Value--34225766.64931866200.895+7%21737620.139+57%14910561.638+130%14192233.101+141%
Usd Book Value Change Per Share---0.023-100%0.016-100%0.012-100%0.013-100%
Usd Book Value Per Share--0.3260.304+7%0.207+57%0.142+130%0.135+141%
Usd Dividend Per Share----0%0.000-100%0.001-100%0.001-100%
Usd Eps--0.0040.025-83%0.015-73%0.009-53%0.001+450%
Usd Free Cash Flow--1769674.3151973090.356-10%1513029.318+17%469711.613+277%-40894.314+102%
Usd Free Cash Flow Per Share--0.0170.019-10%0.014+17%0.004+277%0.000+102%
Usd Free Cash Flow To Equity Per Share--0.0080.011-24%0.007+25%0.006+32%0.012-30%
Usd Price Per Share2.362+15%1.9962.262-12%2.957-33%2.148-7%2.038-2%
Usd Profit--437894.8712572029.209-83%2450266.086-82%1258058.093-65%342293.856+28%
Usd Revenue----0%18064218.980-100%14842117.946-100%15251226.960-100%
Usd Total Gains Per Share---0.023-100%0.016-100%0.013-100%0.014-100%
 EOD+1 -3MRQTTM+11 -21YOY+13 -255Y+16 -2210Y+19 -18

4.2. Fundamental Score

Let's check the fundamental score of AFT Pharmaceuticals Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15565.603
Price to Book Ratio (EOD)Between0-17.236
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.467
Current Ratio (MRQ)Greater than11.280
Debt to Asset Ratio (MRQ)Less than10.534
Debt to Equity Ratio (MRQ)Less than11.146
Return on Equity (MRQ)Greater than0.150.013
Return on Assets (MRQ)Greater than0.050.006
Total2/10 (20.0%)

4.3. Technical Score

Let's check the technical score of AFT Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose3.550
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in NZD. All numbers in thousands.

Summary
 As reported
Total Liabilities -
Total Stockholder Equity+ -
Total Assets = -

Assets

Total Assets-
Total Current Assets77,153
Long-term Assets77,153
Total Current Assets
Net Receivables 28,180
Inventory 39,707
Other Current Assets 471
Total Current Assets  (as reported)77,153
Total Current Assets  (calculated)68,358
+/- 8,795
Long-term Assets
Property Plant Equipment 3,159
Long-term Assets  (as reported)0
Long-term Assets  (calculated)3,159
+/- 3,159

Liabilities & Shareholders' Equity

Total Current Liabilities60,290
Long-term Liabilities-
Total Stockholder Equity-
Total Current Liabilities
Accounts payable 20,771
Other Current Liabilities 2,999
Total Current Liabilities  (as reported)60,290
Total Current Liabilities  (calculated)23,770
+/- 36,520
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Retained Earnings -19,930
Total Stockholder Equity (as reported)0
Total Stockholder Equity (calculated)-19,930
+/- 19,930
Other
Net Tangible Assets 16,185



Balance Sheet

Currency in NZD. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-03-31
> Total Assets 
65,304
58,231
58,231
50,369
50,369
56,603
56,603
59,406
59,406
63,595
63,595
83,230
83,230
0
87,052
0
93,983
0
105,132
0
105,708
0
121,760
0
0
00121,7600105,7080105,132093,983087,052083,23083,23063,59563,59559,40659,40656,60356,60350,36950,36958,23158,23165,304
   > Total Current Assets 
62,055
54,060
54,060
45,101
45,101
48,312
48,312
48,689
48,689
51,261
51,261
54,806
54,806
55,336
55,336
58,549
58,549
67,902
67,902
66,187
66,187
77,542
77,542
77,153
77,153
77,15377,15377,54277,54266,18766,18767,90267,90258,54958,54955,33655,33654,80654,80651,26151,26148,68948,68948,31248,31245,10145,10154,06054,06062,055
       Cash And Cash Equivalents 
28,055
15,980
15,980
7,197
7,197
6,770
6,770
7,400
7,400
6,916
6,916
7,308
7,308
0
6,119
0
5,870
0
3,209
0
5,907
0
7,940
0
0
007,94005,90703,20905,87006,11907,3087,3086,9166,9167,4007,4006,7706,7707,1977,19715,98015,98028,055
       Net Receivables 
15,446
17,403
17,403
16,640
16,640
14,779
14,779
12,993
12,993
16,278
16,278
19,998
19,998
22,627
22,627
16,576
16,576
29,227
29,227
25,705
25,705
29,866
29,866
28,180
28,180
28,18028,18029,86629,86625,70525,70529,22729,22716,57616,57622,62722,62719,99819,99816,27816,27812,99312,99314,77914,77916,64016,64017,40317,40315,446
       Inventory 
17,686
18,718
18,718
21,137
21,137
24,412
24,412
27,815
27,815
25,158
25,158
26,835
26,835
22,734
22,734
35,995
35,995
33,654
33,654
34,129
34,129
33,500
33,500
39,707
39,707
39,70739,70733,50033,50034,12934,12933,65433,65435,99535,99522,73422,73426,83526,83525,15825,15827,81527,81524,41224,41221,13721,13718,71818,71817,686
       Other Current Assets 
868
0
1,959
127
127
176
2,351
481
481
0
2,909
665
665
514
3,856
108
108
64,693
1,812
446
446
100
6,236
471
471
4714716,2361004464461,81264,6931081083,8565146656652,90904814812,3511761271271,9590868
   > Long-term Assets 
3,249
0
4,171
0
0
0
8,291
0
0
0
12,334
0
0
0
31,716
0
0
0
37,230
0
0
0
44,218
0
0
0044,21800037,23000031,71600012,3340008,2910004,17103,249
       Property Plant Equipment 
407
386
386
374
374
330
330
335
335
357
357
4,304
4,304
4,027
4,027
4,017
4,017
3,786
3,786
3,636
3,636
3,360
3,360
3,159
3,159
3,1593,1593,3603,3603,6363,6363,7863,7864,0174,0174,0274,0274,3044,304357357335335330330374374386386407
       Long Term Investments 
0
627
627
1,808
1,808
2,135
2,135
2,493
2,493
3,033
2,905
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000002,9053,0332,4932,4932,1352,1351,8081,8086276270
       Intangible Assets 
2,111
2,548
2,548
2,744
2,744
2,653
5,118
7,089
7,089
2,914
8,239
23,410
23,410
0
26,984
0
30,704
0
32,720
0
35,235
0
38,093
0
0
0038,093035,235032,720030,704026,984023,41023,4108,2392,9147,0897,0895,1182,6532,7442,7442,5482,5482,111
       Other Assets 
0
610
610
342
342
3,173
708
800
800
6,030
705
710
710
12,227
12,227
713
713
17,856
17,856
650
650
24,870
24,870
3,755
3,755
3,7553,75524,87024,87065065017,85617,85671371312,22712,2277107107056,0308008007083,1733423426106100
> Total Liabilities 
37,074
38,761
38,761
37,039
37,039
49,261
49,261
56,446
56,446
58,504
58,504
68,648
68,648
0
69,797
0
64,097
0
68,544
0
64,612
0
65,016
0
0
0065,016064,612068,544064,097069,797068,64868,64858,50458,50456,44656,44649,26149,26137,03937,03938,76138,76137,074
   > Total Current Liabilities 
13,913
15,335
15,335
13,795
13,795
18,607
18,607
14,508
14,508
58,504
58,504
65,015
65,015
25,102
25,102
25,948
25,948
32,102
32,102
25,422
25,422
29,050
29,050
60,290
60,290
60,29060,29029,05029,05025,42225,42232,10232,10225,94825,94825,10225,10265,01565,01558,50458,50414,50814,50818,60718,60713,79513,79515,33515,33513,913
       Short-term Debt 
0
23,426
23,426
23,244
23,244
30,654
30,654
0
0
41,750
41,750
45,808
45,808
0
2,506
0
0
0
5,775
0
0
0
4,542
0
0
004,5420005,7750002,506045,80845,80841,75041,7500030,65430,65423,24423,24423,42623,4260
       Short Long Term Debt 
0
23,426
23,426
23,244
23,244
30,654
30,654
0
0
41,750
39,983
45,808
45,808
0
2,000
0
0
0
5,161
0
0
0
4,000
0
0
004,0000005,1610002,000045,80845,80839,98341,7500030,65430,65423,24423,24423,42623,4260
       Accounts payable 
0
7,348
7,348
10,685
10,685
7,335
7,335
13,245
13,245
6,673
6,673
16,071
16,071
8,622
8,622
18,877
18,877
14,703
14,703
16,431
16,431
12,068
12,068
20,771
20,771
20,77120,77112,06812,06816,43116,43114,70314,70318,87718,8778,6228,62216,07116,0716,6736,67313,24513,2457,3357,33510,68510,6857,3487,3480
       Other Current Liabilities 
5,773
2,261
7,987
0
0
8,053
11,272
0
0
6,628
10,081
2,602
2,602
7,393
13,974
193
193
4,005
11,624
142
142
4,328
12,440
2,999
2,999
2,9992,99912,4404,32814214211,6244,00519319313,9747,3932,6022,60210,0816,6280011,2728,053007,9872,2615,773
   > Long-term Liabilities 
23,161
0
23,426
0
0
0
30,654
0
0
0
0
0
0
0
44,695
0
0
0
36,442
0
0
0
35,966
0
0
0035,96600036,44200044,695000000030,65400023,426023,161
       Long term Debt Total 
0
0
0
0
0
0
30,654
0
41,938
0
0
0
3,633
0
44,695
0
38,149
0
36,442
0
39,190
0
0
0
0
000039,190036,442038,149044,69503,63300041,938030,654000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,242
3,242
0
0
0
0
0
0
0000003,2423,24200000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
2,465
2,465
0
0
5,325
5,325
0
0
11,522
11,522
0
0
17,132
17,132
0
0
22,105
22,105
0
0
0022,10522,1050017,13217,1320011,52211,522005,3255,325002,4652,46500000
> Total Stockholder Equity
28,230
10,346
19,470
13,039
13,039
-2,265
7,342
2,081
2,960
-5,274
5,091
13,087
14,582
0
17,255
0
29,886
0
36,588
0
41,096
0
56,744
0
0
0056,744041,096036,588029,886017,255014,58213,0875,091-5,2742,9602,0817,342-2,26513,03913,03919,47010,34628,230
   Common Stock
53,902
55,994
53,820
63,743
63,743
57,058
54,619
63,743
63,743
57,058
63,743
63,743
63,743
57,061
63,746
77,067
77,067
80,359
77,197
77,489
77,489
80,770
77,606
81,406
81,406
81,40681,40677,60680,77077,48977,48977,19780,35977,06777,06763,74657,06163,74363,74363,74357,05863,74363,74354,61957,05863,74363,74353,82055,99453,902
   Retained Earnings -19,930-19,930-21,416-21,416-37,021-37,021-41,264-41,264-47,684-47,684-49,275-49,275-50,842-51,592-61,006-61,006-61,768-62,289-57,644-57,644-51,349-51,349-44,025-44,025-25,637
   Accumulated Other Comprehensive Income 
-35
0
551
0
0
0
1,243
0
0
0
2,354
0
0
0
2,784
0
0
0
655
0
0
0
554
0
0
005540006550002,7840002,3540001,2430005510-35
   Capital Surplus 0000000000000000000000000
   Treasury Stock0000000000000000000000000



Balance Sheet

Currency in NZD. All numbers in thousands.




Cash Flow

Currency in NZD. All numbers in thousands.




Income Statement

Currency in NZD. All numbers in thousands.


Latest Income Statement (annual, 2022-03-31)

Gross Profit (+$)
totalRevenue129,834
Cost of Revenue-68,539
Gross Profit61,29561,295
 
Operating Income (+$)
Gross Profit61,295
Operating Expense-41,611
Operating Income20,07619,684
 
Operating Expense (+$)
Research Development5,507
Selling General Administrative7,774
Selling And Marketing Expenses28,330
Operating Expense41,61141,611
 
Net Interest Income (+$)
Interest Income4
Interest Expense-2,435
Other Finance Cost-0
Net Interest Income-2,431
 
Pretax Income (+$)
Operating Income20,076
Net Interest Income-2,431
Other Non-Operating Income Expenses-
Income Before Tax (EBT)18,68521,467
EBIT - interestExpense = 17,641
18,685
22,283
Interest Expense2,435
Earnings Before Interest and Taxes (EBIT)20,07621,120
Earnings Before Interest and Taxes (EBITDA)21,120
 
After tax Income (+$)
Income Before Tax18,685
Tax Provision--1,163
Net Income From Continuing Ops19,84819,848
Net Income19,848
Net Income Applicable To Common Shares19,848
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses111,194
Total Other Income/Expenses Net-1,3912,431
 

Technicals of AFT Pharmaceuticals Ltd

1. Trend Indicators

1.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

AFT Pharmaceuticals Ltd Daily Moving Averages ChartAFT Pharmaceuticals Ltd Daily Moving Averages Chart
1.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Let's take a look of the Moving Average Convergence/Divergence (MACD) of AFT Pharmaceuticals Ltd:

    AFT Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) ChartAFT Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
    1.3 Directional Movement Index (DMI)

    The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index).

    The ADX helps you determine the strength of a trend. Let's take a look of the ADX of AFT Pharmaceuticals Ltd:

    • The ADX is .
    AFT Pharmaceuticals Ltd Daily Directional Movement Index (DMI) ChartAFT Pharmaceuticals Ltd Daily Directional Movement Index (DMI) Chart
    1.4 Parabolic SAR

    Shows the current trend and potential entry and exit signals.

    • Parabolic SAR (stop and reverse) is a lagging trend indicator.
    • Shows the current trend.
    • Shows potential entry signals.
    • Shows  potential exit signals.
    • Can be used to place trailing stoplosses..
  • The Parabolic SAR is lower than the price. The current trend is up. +2
  • AFT Pharmaceuticals Ltd Daily Parabolic SAR ChartAFT Pharmaceuticals Ltd Daily Parabolic SAR Chart

    2. Momentum Indicators

    2.1 Relative Strength Index (RSI)

    Measures the speed and change of price movements.

    • Leading momentum indicator, meaning the signals are instant.
    • Ranges between 0 and 100.
    • Above 70 is considered overbought.
    • Below 30 is considered oversold.
    • Above or below 50 can also be used to determine price trend or support and resistance.
    • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
    • Can be used in many different ways
    • The RSI is below 50. -1
    • The RSI is below 30 and oversold. +2
    AFT Pharmaceuticals Ltd Daily Relative Strength Index (RSI) ChartAFT Pharmaceuticals Ltd Daily Relative Strength Index (RSI) Chart
    2.2 Stochastic Oscillator

    Compares a certain price to multiple prices ranging over time.

    • Leading momentum indicator, meaning the signals are instant.
    • Used to determine overbought and oversold areas much like the RSI.
    • Ranges between 0 and 100.
    • Above 80 is considered overbought.
    • Below 20 is considered oversold.
    • Consists of two lines named K and D.
    • K compares the highest high and lowest low on the selected price range.
    • The D line is a moving average of the K line.
    • Can be used to spot divergences
    • The Stochastic is below 50. -1
    • The Stochastic is below 30 and oversold. +2
    AFT Pharmaceuticals Ltd Daily Stochastic Oscillator ChartAFT Pharmaceuticals Ltd Daily Stochastic Oscillator Chart
    2.3 Commodity Channel Index (CCI)
    AFT Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) ChartAFT Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) Chart
    2.4 Chande Momentum Oscillator (CMO)
    AFT Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) ChartAFT Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) Chart
    2.5 Williams %R
    AFT Pharmaceuticals Ltd Daily Williams %R ChartAFT Pharmaceuticals Ltd Daily Williams %R Chart

    3. Volatility Indicators

    3.1 Bollinger Bands
    AFT Pharmaceuticals Ltd Daily Bollinger Bands ChartAFT Pharmaceuticals Ltd Daily Bollinger Bands Chart
    3.2 Average True Range (ATR)
    AFT Pharmaceuticals Ltd Daily Average True Range (ATR) ChartAFT Pharmaceuticals Ltd Daily Average True Range (ATR) Chart

    4. Volume Indicators

    4.1 On-Balance Volume (OBV)
    AFT Pharmaceuticals Ltd Daily On-Balance Volume (OBV) ChartAFT Pharmaceuticals Ltd Daily On-Balance Volume (OBV) Chart
    4.2 Money Flow Index (MFI)
    AFT Pharmaceuticals Ltd Daily Money Flow Index (MFI) ChartAFT Pharmaceuticals Ltd Daily Money Flow Index (MFI) Chart

    5. Summary

    5.1. Notifications

    TypeNotificationDate
    PenkeCurrently no notifications for AFT Pharmaceuticals Ltd.

    5.2. Trading Signals

    DateIndicatorEntry signalExit signal
    2023-05-26CMO LONG ENTRY SHORT CLOSE50 crossover to upside
    2023-05-29CMO LONG ENTRY SHORT CLOSE50 crossover to upside
    2023-05-30CMO LONG ENTRY SHORT CLOSE50 crossover to upside
    2023-05-31CCI LONG ENTRY SHORT CLOSE100 crossover to upside
    CMO LONG ENTRY SHORT CLOSE50 crossover to upside
    2023-06-01CMO LONG ENTRY SHORT CLOSE50 crossover to upside
    2023-06-02CMO LONG ENTRY SHORT CLOSE50 crossover to upside

    5.2. Technical Score

    Let's check the technical score of AFT Pharmaceuticals Ltd based on Penke's default Symbol scanner.

    Penke's Symbol Scanner

      
      
    IndicatorConditionValue
    OpenGreater thanClose3.550
    Total0/1 (0.0%)

    Comments

    Join the conversation.

    Leave a comment

    Stay informed about AFT Pharmaceuticals Ltd.

    Receive notifications about AFT Pharmaceuticals Ltd in your mailbox!